Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novo Nordisk On Friday, CEO Lars Frugenaard, Wegovy-Maker’s growing competition goes down as he tries to revive their luck.
Denmark said that the medicinal giant would remain in the post of Jørgensen, “it’s a while to support a smooth passage to the new management.” Added that it continues in search of a replacement and an announcement will be done on time.
Novo Nordisk shares were 3% lower than last trading. Meanwhile, the shares of the rival obesity drug manufacturer Eli lilli The premarket increased by 1.6% in trade.
The decision, Novo Nordiskin’s share price, the competition in the competition in the competition and disappointed the results of the disappointment for the treatment of further generation, a braunti threw a braunt.
The company’s stock price is currently more than 50% since mid 2024.
“Novo Nordiskin strategy remains unchanged and the board is confident in the ability to execute the company’s current work plans and plans,” he said.
“Changes in Novo Nordisk, since mid-2024, the company’s share price and since mid-2024 are among the company’s share price development,” he said.
In connection with the change, the company, chairman of the Novo Nordisk Foundation Lars Rerien Sørensen, will first connect to the NODIC NORDISK board, he said.
Novo last week reported to be lower than expected The first quarter of the flag ship, Obesic Medicine and Interviews Competition Competition competition in the Amid Amiss has a full annual sales growth forecast for the forecast
“Inks took part of our work,” Jørgensen said CNBC’s Charlotte Reed.
The company said that sales were made in the second half of the year because they completed the result of the expected to improve the second half of the sale in the second half of the year, the food and drug administration (FDA) drug deficiency.
Novo struggled to shake negative feelings after watching a number Disappointing test results The next generation is for obesity medicinal candidate Cagrisema. Jørgensen said he was “very optimistic” about the prospects of treatment.
“CAGRISEMA is the best product that has been tested or marketed, and we believe we can further improve this information.”
